| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6858618 (Pediatric) | IPR | Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia |
Jun, 2022
(1 year, 3 months ago) | |
Crestor is owned by Ipr.
Crestor contains Rosuvastatin Calcium.
Crestor has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Crestor are:
- US6858618*PED
Crestor was authorised for market use on 12 August, 2003.
Crestor is available in tablet;oral dosage forms.
The generics of Crestor are possible to be released after 27 May, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | May 27, 2023 |
Drugs and Companies using ROSUVASTATIN CALCIUM ingredient
Market Authorisation Date: 12 August, 2003
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of CRESTOR before it's drug patent expiration?
More Information on Dosage
CRESTOR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic